Key result
Doxorubicin causes acute cardiomyocyte toxicity and alters genes linked to late-onset cardiotoxicity.
Why the study?
Doxorubicin use is associated with severe cardiotoxicity that can occur years after treatment, and optimal biomarkers for late-onset toxicity are lacking.
Does doxorubicin exposure induce specific biomarker changes in human embryonic stem cell-derived cardiomyocytes?
Does doxorubicin exposure induce specific biomarker changes in human embryonic stem cell-derived cardiomyocytes?
Global transcriptional profiling identified novel gene clusters that may serve as sensitive biomarkers for late-onset doxorubicin-induced cardiotoxicity, whereas cTnT is useful for acute toxicity.
Answers are grounded in this paper and cite their sources.
Does not support clinical biomarker adoption; leaves open predictive value for late doxorubicin cardiotoxicity in patients.
Doxorubicin is a chemotherapeutic agent indicated for the treatment of a variety of cancer types, including leukaemia, lymphomas, and many solid tumours. The use of doxorubicin is, however, associated with severe cardiotoxicity, often resulting in early discontinuation of the treatment. Importantly, the toxic symptoms can occur several years after the termination of the doxorubicin administration. In this study, the toxic effects of doxorubicin exposure have been investigated in cardiomyocytes derived from human embryonic stem cells (hESC). The cells were exposed to different concentrations of doxorubicin for up to 2 days, followed by a 12 day recovery period. Notably, the cell morphology was altered during drug treatment and the cells showed a reduced contractile ability, most prominent at the highest concentration of doxorubicin at the later time points. A general cytotoxic response measured as Lactate dehydrogenase leakage was observed after 2 days' exposure compared to the vehicle control, but this response was absent during the recovery period. A similar dose-dependant pattern was observed for the release of cardiac specific troponin T (cTnT) after 1 day and 2 days of treatment with doxorubicin. Global transcriptional profiles in the cells revealed clusters of genes that were differentially expressed during doxorubicin exposure, a pattern that in some cases was sustained even throughout the recovery period, suggesting that these genes could be used as sensitive biomarkers for doxorubicin-induced toxicity in human cardiomyocytes. The results from this study show that cTnT release can be used as a measurement of acute cardiotoxicity due to doxorubicin. However, for the late onset of doxorubicin-induced cardiomyopathy, cTnT release might not be the most optimal biomarker. As an alternative, some of the genes that we identified as differentially expressed after doxorubicin exposure could serve as more relevant biomarkers, and may also help to explain the cellular mechanisms behind the late onset apoptosis associated with doxorubicin-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Holmgren et al. (2014) studied doxorubicin-induced cardiotoxicity. Doxorubicin vs. vehicle control was evaluated on cytotoxicity (LDH leakage), cTnT release, and global transcriptional profiles. Doxorubicin exposure in human embryonic stem cell-derived cardiomyocytes induced acute cytotoxicity and altered gene expression profiles that may serve as biomarkers for late-onset cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: